Poptika / Shutterstock.com
Patent applicants with digital health inventions need to remember that being useful and novel may not be enough, warn Linda Thayer, Aaron Capron and Sneha Nyshadham of Finnegan, Henderson, Farabow, Garrett & Dunner.
Digital healthcare technologies are transforming the healthcare industry and quickly changing the way healthcare is delivered. Disruptive technologies such as artificial intelligence, together with faster processing devices, have made it possible to analyse and predict risk and outcomes, sometimes in real time.
Despite these substantial benefits, some of the most innovative solutions face significant hurdles to obtaining patent protection. In two precedential opinions the US Court of Appeals for the Federal Circuit upheld the rejection of two patent applications in the field of bioinformatics as not patentable subject matter under 35 USC §101.
Bioinformatics uses a combination of computer processing and biological or genetic information to detect and diagnose medical conditions. The rejected patent applications dealt with computerised methods and systems for determining or resolving haplotype phase. Haplotype phasing is a process for determining the parent from whom alleles (ie, versions of a gene) are inherited.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Finnegan, patent eligibility, healthcare, novelty, inventions, technologies, US Court of Appeals for the Federal Circuit, genetics, PTAB, biologics
